Jonathan E. Rosenberg

Also affiliated with Memorial Sloan Kettering Cancer Center, Cornell University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

1.8Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1283

Top 12%

1.8DataRank

Top 12%68 citations

Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more

Papers

Driven by 59 papers — median percentile 44. Top paper: “Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial”.

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00004-8

N/A

5.8DataRank · unranked

418 citations

Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano +21 more

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02887

N/A

4.4DataRank · unranked

181 citations

Matthew I. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar +20 more

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.01485

N/A

3.3DataRank · unranked

100 citations

Michael Lattanzi, Karissa Whiting, Hikmat Al‐Ahmadie, Colleen Quinlan, Min Yuen Teo +34 more

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

Nature Communications(2022)10.1038/s41467-022-29342-0

N/A

2.1DataRank · unranked

82 citations

Samuel A. Funt, Annie Borch, Kamilla Kjærgaard Munk, Anne-Mette Bjerregaard, James L. Reading +17 more

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1283

Top 12%

1.8DataRank

Top 12%68 citations

Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

British Journal of Cancer(2021)10.1038/s41416-020-01244-2

N/A

1.6DataRank · unranked

40 citations

Hikmat Al‐Ahmadie, Kenneth Seier, Christopher Tully, Ashley Marie Regazzi, Eugene J. Pietzak +15 more

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

Cell(2022)10.1016/j.cell.2022.01.003

N/A

0.973DataRank · unranked

654 citations

Christopher J. Fong, Anisha Luthra, Shaleigh Smith, Renzo G. DiNatale, Subhiksha Nandakumar +70 more

Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy

British Journal of Urology(2021)10.1111/bju.15428

N/A

0.951DataRank · unranked

25 citations

Emily Vertosick, Daniel D. Sjoberg, Nathan C. Wong, Chun Huang, Eugene J. Pietzak +10 more

Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.05.005

N/A

0.937DataRank · unranked

33 citations

Brendan J. Guercio, Arshi Arora, Xueli Hao, Ashley Marie Regazzi, Timothy F. Donahue +25 more

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology(2025)10.1200/jco-25-01608

N/A

0.674DataRank · unranked

20 citations

Matthew D. Galsky, Nazlı Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al‐Ahmadie +39 more

Fundamental immune–oncogenicity trade-offs define driver mutation fitness

Nature(2022)10.1038/s41586-022-04696-z

N/A

0.663DataRank · unranked

82 citations

Roberta Zappasodi, Isabell Schulze, Zachary Sethna, Kelvin C. de Andrade, Dean F. Bajorin +25 more

Genomic heterogeneity as a barrier to precision oncology in urothelial cancer

Cell Reports(2022)10.1016/j.celrep.2022.111859

N/A

0.648DataRank · unranked

74 citations

Ziyu Chen, Hannah Wise, Andrew T. Lenis, Shweta S. Chavan, Mark T.A. Donoghue +20 more

Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications

Modern Pathology(2024)10.1016/j.modpat.2024.100557

N/A

0.646DataRank · unranked

18 citations

Karissa Whiting, Min-Yuen Teo, Jacob E. Tallman, Gamze Gokturk Ozcan, Merve Başar +21 more

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

Genome Medicine(2021)10.1186/s13073-021-00898-8

N/A

0.614DataRank · unranked

59 citations

Michael L. Cheng, Maha Shady, Julie L. Yang, Dennis Stephens, Helen Won +32 more

Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts

Nature Communications(2020)10.1038/s41467-020-15885-7

N/A

0.612DataRank · unranked

58 citations

Wenhuo Hu, François Audenet, Nima Almassi, Aphrothiti J. Hanrahan, Katie S. Murray +32 more

Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3322

N/A

0.574DataRank · unranked

45 citations

Zoe Steinsnyder, Vignesh Ravichandran, Kaitlyn Tkachuk, Yelena Kemel, Chaitanya Bandlamudi +16 more

Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade

Nature Medicine(2023)10.1038/s41591-023-02544-9

N/A

0.550DataRank · unranked

38 citations

Michael B. Foote, Benoı̂t Rousseau, Henry Walch, Yelena Kemel, Allison L. Richards +33 more

Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma

European Urology(2025)10.1016/j.eururo.2025.04.008

N/A

0.489DataRank · unranked

25 citations

Ziyu Chen, Karissa Whiting, Irina Ostrovnaya, Andrew T. Lenis, Timothy N. Clinton +26 more

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4505

N/A

0.470DataRank · unranked

22 citations

Jonathan E. Rosenberg, Rana R. McKay, Thomas W. Flaig, Daniel P. Petrylak, Christopher Hoimes +14 more

Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A–menin to bivalent promoters

Nature Genetics(2025)10.1038/s41588-024-02015-y

N/A

0.434DataRank · unranked

17 citations

Mohini R. Pachai, Dan Li, Cindy J. Lee, Sarah Warda, Makhzuna N. Khudoynazarova +25 more

Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1006

N/A

0.416DataRank · unranked

15 citations

Karissa Whiting, Preethi Srinivasan, Chaitanya Bandlamudi, Aliya Khurram, Vijai Joseph +26 more

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4607

N/A

0.385DataRank · unranked

12 citations

Karla V. Ballman, Matt D. Galsky, Michael J. Morris, Ronald C. Chen, Timothy A. Chan +9 more

Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma

European Urology(2024)10.1016/j.eururo.2024.10.024

N/A

0.385DataRank · unranked

12 citations

Syed M. Alam, Fengshen Kuo, Ziyu Chen, Wesley Yip, Andrew Katims +34 more

Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort

European Urology(2025)10.1016/j.eururo.2025.08.012

N/A

0.357DataRank · unranked

9 citations

Melissa Assel, Gopa Iyer, Scot A. Niglio, Bernard H. Bochner, Guido Dalbagni +28 more

A Quantitative Multiparametric MRI Analysis Platform for Estimation of Robust Imaging Biomarkers in Clinical Oncology

Tomography(2023)10.3390/tomography9060161

N/A

0.345DataRank · unranked

9 citations

Ramesh Paudyal, Amaresha Shridhar Konar, Peter S. LaViolette, Oğuz Akın, Vaios Hatzoglou +8 more

Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer

Nature Communications(2025)10.1038/s41467-025-62710-0

N/A

0.330DataRank · unranked

8 citations

Henry M. Delavan, Elizabeth Yip, Corynn Kasap, Jun Zhu, Roshan Lodha +21 more

Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.440

N/A

0.312DataRank · unranked

7 citations

Jonathan Coleman, Nathan C. Wong, Daniel D. Sjoberg, Bernard H. Bochner, Guido Dalbagni +15 more

Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer

European Urology(2025)10.1016/j.eururo.2025.07.011

N/A

0.292DataRank · unranked

6 citations

Siyuan Guo, Bin Luo, Chenxi Yu, Todd P. Knutson, Anna Kobilka +13 more

Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer

JCO Precision Oncology(2024)10.1200/po.23.00274

N/A

0.292DataRank · unranked

6 citations

Karissa Whiting, Vignesh Ravichandran, Jacob E. Tallman, Syed M. Alam, Carissa Chu +29 more

Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4526

N/A

0.269DataRank · unranked

5 citations

Jatin Gandhi, Min Yuen Teo, Michael Lattanzi, Samuel A. Funt, David H. Aggen +14 more

Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4522

N/A

0.269DataRank · unranked

5 citations

Catherine M. Tangen, Michal Sarfaty, Ashley Marie Regazzi, I-Ling C. Lee, Woonyoung Choi +6 more

Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)

European Urology Open Science(2025)10.1016/j.euros.2025.03.009

N/A

0.208DataRank · unranked

3 citations

Karissa Whiting, Ronak Shah, Karla V. Ballman, Susan Halabi, Ashley Marie Regazzi +10 more

Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4584

N/A

0.165DataRank · unranked

2 citations

Alexander Solovyov, Jayon Lihm, Colleen Quinlan, Karissa Whiting, Hao Li +15 more

Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.523

N/A

0.165DataRank · unranked

2 citations

Rania Sheikh, Yelena Kemel, Manuel De Jesus Escano, Aliya Khurram, Peter A. Reisz +15 more

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4598

N/A

0.165DataRank · unranked

2 citations

Neha Ratna, David Gavrilov, Cihan Düzgöl, Mahnoor Akhlaq, Min Yuen Teo +15 more

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4562

N/A

0.104DataRank · unranked

1 citations

Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat Al‐Ahmadie, Jonathan E. Rosenberg +12 more

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4609

N/A

0.104DataRank · unranked

1 citations

Karla V. Ballman, Matt D. Galsky, Michael J. Morris, Srikala S. Sridhar, Ronald C. Chen +7 more

Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps589

N/A

0DataRank · unranked

1 citations

Karla V. Ballman, Scott T. Tagawa, Alan Tan, Bishoy M. Faltas, Arshin Sheybani +11 more

Data from Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer

(2023)10.1158/1078-0432.c.6531197

Top 100%

0DataRank

Top 100%0 citations

Zoe Steinsnyder, Vignesh Ravichandran, Kaitlyn Tkachuk, Yelena Kemel, Chaitanya Bandlamudi +16 more

Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer

(2023)10.1158/1078-0432.c.6532764

N/A

0DataRank · unranked

0 citations

Karissa Whiting, Preethi Srinivasan, Chaitanya Bandlamudi, Aliya Khurram, Vijai Joseph +26 more

Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer

(2023)10.1158/1078-0432.c.6532764.v1

N/A

0DataRank · unranked

0 citations

Karissa Whiting, Preethi Srinivasan, Chaitanya Bandlamudi, Aliya Khurram, Vijai Joseph +26 more

An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4614

N/A

0DataRank · unranked

0 citations

Christopher Gaffney, Christian Hernández, Patricia Morán, Kara Worth, Melissa McCarter +9 more

Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3882

N/A

0DataRank · unranked

23 citations

Carissa Chu, Jonathan E. Rosenberg, David H. Aggen

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis

BMJ Oncology(2024)10.1136/bmjonc-2024-000335

N/A

0DataRank · unranked

20 citations

Giovanni Maria Iannantuono, Saad Atiq, Dilara Akbulut, Ninet Sinaii, Nicholas I. Simon +11 more

Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4504

N/A

0DataRank · unranked

42 citations

Matthew I. Milowsky, Peter H. O’Donnell, Ajjai Alva, Marisa Kollmeier, Tracy L. Rose +15 more

Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2020.12.002

N/A

0DataRank · unranked

2 citations

Darren R. Feldman, Michael J. Morris, Robert J. Motzer, Dana E. Rathkopf, Ashley Marie Regazzi +5 more

Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies

Cancers(2023)10.3390/cancers15225468

N/A

0DataRank · unranked

18 citations

Alfonso Lema-Dopico, Ramesh Paudyal, Amaresha Shridhar Konar, Thomas L. Chenevert, Dariya Malyarenko +8 more

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma

UNC Libraries(2024)10.17615/6gs3-hm85

N/A

0DataRank · unranked

0 citations

Irina Ostrovnaya, Matthew I. Milowsky, Jonathan E. Rosenberg, Wassim Abida, Dean F. Bajorin +6 more

Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC).

Carolina Digital Repository (University of North Carolina at Chapel Hill)(2024)10.17615/7y09-8d51

N/A

0DataRank · unranked

0 citations

Evan Y. Yu, Lauren C. Harshman, Nielsen, Matthew Edward, Yu‐Ning Wong, Andrew Z. Wang +14 more

Dermatologic infections in cancer patients treated with checkpoint inhibitors

Journal of the American Academy of Dermatology(2021)10.1016/j.jaad.2021.03.039

N/A

0DataRank · unranked

8 citations

Dulce M. Barrios, Gregory S. Phillips, Michael A. Postow, Allison Betof Warner, Jonathan E. Rosenberg +4 more

Developing Precision Medicine for Bladder Cancer

Hematology/Oncology Clinics of North America(2021)10.1016/j.hoc.2021.02.008

N/A

0DataRank · unranked

34 citations

Gopa Iyer, Jonathan E. Rosenberg, Brendan J. Guercio

Association of radical cystectomy and increased risk of skeletal-related events in bone-metastatic urothelial carcinoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.477

N/A

0DataRank · unranked

0 citations

Imaani Easthausen, Soleen Ghafoor, Paul J. Christos, Timothy F. Donahue, Jonathan E. Rosenberg +2 more

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4521

N/A

0DataRank · unranked

0 citations

Susan Halabi, Bin Luo, Jonathan E. Rosenberg, Woonyoung Choi, Hikmat Al‐Ahmadie +12 more

Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2020.02.014

N/A

0DataRank · unranked

46 citations

Christopher Tully, Emily C. Zabor, Bernard H. Bochner, Guido Dalbagni, Harry W. Herr +8 more

Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4616

N/A

0DataRank · unranked

1 citations

David A. Knorr, Karissa Whiting, Venkatraman Seshan, Eugene J. Pietzak, Timothy F. Donahue +10 more

Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.498

N/A

0DataRank · unranked

12 citations

Eugene J. Pietzak, Samantha Brown, Jie‐Fu Chen, Vanessa Peters, Ashley Marie Regazzi +15 more

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade

Journal of Clinical Oncology(2023)10.1200/jco.22.02144

N/A

0DataRank · unranked

18 citations

Mahdi Golkaram, Samuel A. Funt, Hikmat Al‐Ahmadie, Shannon Kaplan, Fan Song +11 more

Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e16519

N/A

0DataRank · unranked

0 citations

Min Yuen Teo, Samuel A. Funt, Chung‐Han Lee, David H. Aggen, Neha Ratna +11 more

Jonathan E. Rosenberg

Indexed papers

Top data-sharing exemplar

Papers